Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-3.27 Insider Own2.30% Shs Outstand350.22M Perf Week-4.57%
Market Cap4.82B Forward P/E3.93 EPS next Y3.50 Insider Trans0.37% Shs Float343.64M Perf Month-4.31%
Income-1143.00M PEG- EPS next Q0.92 Inst Own66.80% Short Float11.66% Perf Quarter4.71%
Sales9.22B P/S0.52 EPS this Y-714.90% Inst Trans20.04% Short Ratio2.42 Perf Half Y28.45%
Book/sh11.23 P/B1.23 EPS next Y-5.12% ROA-2.60% Target Price- Perf Year-49.19%
Cash/sh3.47 P/C3.97 EPS next 5Y-9.43% ROE-30.20% 52W Range8.31 - 27.84 Perf YTD-5.17%
Dividend- P/FCF2.21 EPS past 5Y61.43% ROI-1.60% 52W High-49.39% Beta-0.38
Dividend %- Quick Ratio1.10 Sales past 5Y31.90% Gross Margin72.20% 52W Low69.54% ATR0.46
Employees21500 Current Ratio1.30 Sales Q/Q-7.70% Oper. Margin-4.20% RSI (14)46.35 Volatility2.36% 3.34%
OptionableYes Debt/Eq7.28 EPS Q/Q87.60% Profit Margin-12.40% Rel Volume0.74 Prev Close13.77
ShortableYes LT Debt/Eq7.03 EarningsAug 08 BMO Payout- Avg Volume16.59M Price14.09
Recom3.00 SMA201.91% SMA50-6.83% SMA2002.83% Volume2,149,344 Change2.32%
Aug-03-17Reiterated RBC Capital Mkts Sector Perform $19 → $21
Jun-16-17Initiated Cantor Fitzgerald Overweight $18
May-10-17Reiterated RBC Capital Mkts Sector Perform $18 → $19
Apr-20-17Reiterated JP Morgan Neutral $15 → $10
Mar-23-17Reiterated RBC Capital Mkts Sector Perform $21 → $18
Mar-06-17Reiterated Rodman & Renshaw Neutral $23 → $17
Feb-27-17Reiterated Mizuho Underperform $11 → $9
Feb-14-17Reiterated RBC Capital Mkts Sector Perform $29 → $22
Feb-10-17Reiterated Barclays Equal Weight $34 → $20
Jan-04-17Reiterated Piper Jaffray Underweight $16 → $11
Dec-15-16Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $17
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Nov-10-16Downgrade Rodman & Renshaw Buy → Neutral $81 → $23
Nov-09-16Reiterated RBC Capital Mkts Sector Perform $35 → $29
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Sep-19-17 11:01AM  GlassHouse: NuVasive Using The 'Valeant Playbook' To Deceive Investors Benzinga
Sep-18-17 10:33AM  Valeant Pharmaceuticals: Is A New Drug Approval On The Horizon? Barrons.com
09:54AM  What You Should Know About The Drug Approval Valeant Could Receive This Week Benzinga
07:00AM  Valeant To Participate At The Cantor Fitzgerald Global Healthcare Conference CNW Group
Sep-15-17 09:00AM  Valeant Commits $200,000 to Support Hurricane Relief Efforts CNW Group
08:26AM  Own Alphabet Inc. Stock? Antitrust Is on the Horizon InvestorPlace
Sep-12-17 09:14AM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Is STILL Too Ugly to Buy InvestorPlace
08:01AM  See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc. Markit
08:00AM  Today's Research Reports on Trending Tickers: Endo International and Valeant Pharmaceuticals ACCESSWIRE
Sep-11-17 02:35PM  DST faces class action over profit-sharing plan American City Business Journals
09:49AM  Buy Amazon, short Valeant among the top picks out of last year's Delivering Alpha CNBC
Sep-08-17 02:00PM  Follow the Crucial '$20 Level Rule' When Trading Stocks TheStreet.com
10:06AM  This Clear Catalyst Sent Valeant Pharmaceuticals Intl. Inc. 18% Lower in August Motley Fool
08:00AM  $20 Should Be Your Cutoff Point TheStreet.com
Sep-06-17 07:00AM  Valeant To Participate At The Morgan Stanley Global Healthcare Conference PR Newswire
Sep-05-17 04:51PM  Why Mallinckrodt Got Crushed Barrons.com
09:20AM  Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118 PR Newswire
09:20AM  Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118 CNW Group
08:00AM  See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc. Markit
07:20AM  Corporate News Blog - Intellipharmaceutics International Announces Appointment of CFO ACCESSWIRE
Sep-02-17 12:03PM  Better Buy: Valeant Pharmaceuticals International, Inc. vs. Rite Aid Corporation Motley Fool
Sep-01-17 05:39PM  Valeant (VRX) Continues to Lose Ground: Can It Bounce Back? Zacks
09:19AM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Will Be Just Fine InvestorPlace
09:02AM  The Simple Reason I Won't Buy Intrexon Motley Fool
Aug-31-17 09:30AM  Wilmington company sues former partner following work for Salix, Valeant American City Business Journals
08:00AM  See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc. Markit
Aug-30-17 02:27PM  A Group Of Investors Is On A Mission To Help Traders Give Back Through Charity Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Rexahn Pharmaceuticals and Valeant Pharmaceuticals ACCESSWIRE
Aug-29-17 04:41PM  Why Finish Line Inc (FINL), Valeant Pharmaceuticals Intl Inc (VRX) and Best Buy Co Inc (BBY) Are 3 of Todays Worst Stocks InvestorPlace -6.96%
01:14PM  Valeant: No Fundamental Reasons for Today's Selloff? Barrons.com
12:43PM  Why Did Valeant Pharmaceuticals (VRX) Stock Fall Today? Zacks
10:23AM  Battered Teva Pharmaceutical Industries Ltd (ADR) Stock Still Is Toxic InvestorPlace
09:34AM  Valeant Pharmaceuticals: Weakness, Weakness Everywhere? Barrons.com
Aug-28-17 01:23PM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Falls on New Legal Battle InvestorPlace
07:23AM  Immune Designs quest for a cancer vaccine could go the distance MarketWatch
Aug-25-17 05:53PM  ETFs with exposure to Valeant Pharmaceuticals International, Inc. : August 25, 2017 Capital Cube
04:39PM  Why Ulta Beauty Inc (ULTA), Valeant Pharmaceuticals Intl Inc (VRX) and GameStop Corp. (GME) Are 3 of Todays Worst Stocks InvestorPlace
12:35PM  Is the Valeant Pharmaceuticals Intl Inc (VRX) Debt Situation Overblown? InvestorPlace
10:00AM  Valeant's Legal Bills Are Piling Up Following Latest Securities Fraud Lawsuit TheStreet.com
09:45AM  Valeant: The Long or Short of It Barrons.com
05:00AM  Valeants Latest Legal Threat Could Be Especially Costly Bloomberg
Aug-24-17 09:13AM  Here's the Simple Issue I Still Have With Valeant Pharmaceuticals (and Why You Shouldn't Buy) Motley Fool
Aug-21-17 09:34AM  What's The FDA Saying About Valeant's Manufacturing Facility Issues? Benzinga
08:01AM  See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc. Markit
08:00AM  Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals Intl Inc. and VIVUS Inc. ACCESSWIRE
Aug-18-17 09:53AM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Is a Gamble You Can Win InvestorPlace
08:00AM  See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc. Markit
07:39AM  Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain TheStreet.com
Aug-17-17 11:27AM  Why Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Higher Today InvestorPlace
09:38AM  Valeant: Hard to Ignore the Positive Developments? Barrons.com
07:50AM  Valeants Tampa manufacturing plant on track for a better bill of health American City Business Journals
Aug-16-17 07:24PM  Valeant Pharmaceuticals: Cramer's Top Takeaways TheStreet.com
07:18PM  Valeant's Papa: 'It's been a challenging 15 months, but w... CNBC Videos
06:41PM  Valeant Pharmaceuticals CEO Joe Papa: 'It's been a challe... CNBC Videos
06:26PM  Valeant Pharmaceuticals CEO: 'It's been a challenging 15 months, but we've made great progress' CNBC
04:49PM  Valeant Pharma works to resolve FDA concerns at Tampa plant MarketWatch
04:15PM  Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility PR Newswire
04:15PM  Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility CNW Group
11:25AM  Valeant Pharmaceuticals International, Inc. :VRX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 Capital Cube
10:16AM  The Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak InvestorPlace
Aug-14-17 11:49AM  The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant Zacks
Aug-12-17 08:01AM  See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc. Markit
Aug-11-17 10:20AM  When the drugmaker raised these heart drugs prices, patients stopped getting them MarketWatch
09:59AM  Valeant: Three Steps to a Recovery? Barrons.com
07:05AM  Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure Zacks
Aug-10-17 07:22PM  Robert Bruce Invests in Valvoline, 2 Pharmaceutical Companies GuruFocus.com
09:03AM  5 Reasons Valeant's Situation Could Get Worse Motley Fool
Aug-09-17 06:36PM  Valeant and Teva Share Similar Ambitions With Similar Pitfalls TheStreet.com -10.04%
06:05PM  Paulson & Co., Inc. Reiterates Confidence In Valeant Strategy PR Newswire
06:05PM  Paulson & Co., Inc. Reiterates Confidence In Valeant Strategy CNW Group
04:38PM  Earnings Hangover Sacks Valeant Pharmaceuticals' Stock, Sending Shares Down 10% Motley Fool
04:30PM  Why Priceline Group, Office Depot, and Valeant Pharmaceuticals International Slumped Today Motley Fool
04:15PM  Here's Why Progenics Pharmaceuticals, Inc. Lost Ground Today Motley Fool
04:04PM  CANADA STOCKS-TSX ends lower as Valeant, financials drag Reuters
03:23PM  Valeant Isn't Out Of The Woods Yet Benzinga
03:08PM  Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View Zacks
12:02PM  Valeant Isn't Out of Trouble Yet, Debt Remains Difficult to Curb TheStreet.com
09:45AM  Wednesdays Vital Data: Bank of America Corp (BAC), SeaWorld Entertainment Inc. (SEAS) and BP plc (ADR) (BP) InvestorPlace
09:41AM  Valeant: A Plausible Path Forward? Barrons.com
09:32AM  Your first trade for Wednesday, August 9 CNBC
09:16AM  Finally! 3 Figures From Valeant's Second-Quarter Report That Demonstrate Improvement Motley Fool
08:20AM  Valeant is on track to reduce about $5 billion of debt. But it has more than $27 billion to go MarketWatch
08:10AM  Today's Research Reports on Stocks to Watch: Esperion Therapeutics and Valeant Pharmaceuticals ACCESSWIRE
07:40AM  Working on a turnaround, Valeant gets a setback from its Bausch & Lomb plant in Tampa American City Business Journals
Aug-08-17 06:03PM  Valeant Rises on Earnings Beat, Progress on Debt Repayment GuruFocus.com
05:58PM  Valeant reports 2Q loss Associated Press
04:34PM  Valeant Bonds Rise on Early Debt Repayment Barrons.com
03:15PM  [$$] Valeant/Teva: lost summer Financial Times
03:06PM  Valeant Pharmaceuticals: Bears Will Be Bears Barrons.com
02:34PM  Here's Why Valeant Pharmaceuticals Intl. Inc. Surged as Much as 10% Motley Fool
01:17PM  Valeant Shares Gain on Strength of Xifaxan Bloomberg Video
12:21PM  [$$] Valeant gains breathing room during recovery Financial Times
11:47AM  Valeant Pharmaceuticals' Debt Reduction Overshadows Drop in Revenue Motley Fool
11:45AM  Valeant says it will exceed debt repayment target, shares surge Reuters
11:35AM  Valeant: Time, Time, Time is on My Side Barrons.com
11:28AM  Valeant's Guidance Gymnastics Point to a Cut Bloomberg
11:05AM  Is This the Turnaround Valeant Pharma Has Been Waiting For? 24/7 Wall St.
11:00AM  CANADA STOCKS-TSX up on Valeant, Ritchie results; BlackBerry falls on sell rating Reuters
10:32AM  ADP Stock Breakout Just Getting Started Investopedia
10:23AM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Scores 2 Vital Victories InvestorPlace
Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex. It also provides SofLens daily disposable contact lenses; ophthalmic surgical products; PureVision, a silicone hydrogel; Biotrue ONEday daily disposable contact lenses; Bausch + Lomb Ultra, a silicone hydrogel replacement contact lens; and medical device systems. In addition, the company offers Xifaxan for the treatment of irritable bowel syndrome; Provenge for the treatment of prostate cancer; Uceris to get ulcerative colitis under control; Arestin, a subgingival sustained-release antibiotic; Jublia for the treatment of onychomycosis; Solodyn for the treatment of acne; Elidel to treat skin conditions; and Glumetza tablets to enhance glycemic control. Further, it provides Wellbutrin XL for the treatment of major depressive disorder; Isuprel injections; Xenazine for the treatment of chorea; Nitropress for the reduction of blood pressure of patients in hypertensive crises; Cuprimine to treat Wilson's disease; Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DE SCHUTTER RICHARD UDirectorAug 21Buy14.3310,000143,29682,379Aug 22 04:39 PM
DE SCHUTTER RICHARD UDirectorMay 11Buy13.9020,000278,00070,572May 15 05:19 PM
DE SCHUTTER RICHARD UDirectorMar 15Buy10.8010,000108,00025,190Mar 16 05:12 PM
Herendeen PaulEVP and CFOMar 14Buy10.7224,000257,280174,000Mar 16 05:04 PM
ValueAct Holdings, L.P.DirectorMar 14Buy10.823,000,00032,465,00016,937,431Mar 16 04:31 PM
Pershing Square Capital ManageDirectorMar 13Sale11.0018,114,432199,258,7520Mar 14 04:14 PM
Ross Thomas W. Sr.DirectorDec 14Buy14.735,00073,65026,822Dec 16 04:19 PM
Pershing Square Capital ManageDirectorDec 12Sale14.853,476,69051,628,84718,114,432Dec 13 04:14 PM